FDA
-
-
-
-
-
-
-
Cantor Fitzgerald Maintains ProQR Therapeutics N.V. (PRQR) at Overweight with $3.50 Price Target
-
-
-
-
-
-
-
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
-
-
-
-
-
-
-
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
-
-
-
-
-
-
-
ProQR Announces Virtual Presentation at EURETINA 2021
-
-
-
-
-
-
-
ProQR (PRQR) Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
-
-
-
-
-
-
-
ProQR (PRQR) Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
-
-
-
-
-
-
-
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

